Surgery for recurrent adrenocortical carcinoma: A multicenter retrospective study

详细信息    查看全文

• 作者：Gué ; nolé ; Simon ; MD^a ; Franç ; ois Pattou ; MD ; PhD^b ; Eric Mirallié ; MD^a ; Jean Christophe Lifante ; MD ; PhD^c ; Claire Nominé ; MD^d ; Vincent Arnault ; MD^e ; Loï ; c de Calan ; MD^e ; Cé ; cile Caillard ; MD^a ; Bruno Carnaille ; MD^b ; Laurent Brunaud ; MD ; PhD^d ; Nathalie Laplace ; MD^c ; Robert Caiazzo ; MD ; PhD^b ; Claire Blanchard ; MD^a ; ^{claire.blanchard@chu-nantes.fr}
• 刊名：Surgery
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：161
• 期：1
• 页码：249-256
• 全文大小：224 K
• 卷排序：161

文摘

Adrenocortical carcinoma is a rare neoplasm with a high rate of recurrence. We studied the impact of surgery on the survival in recurrent adrenocortical carcinoma patients.MethodsWe performed a retrospective review of patients with recurrent adrenocortical carcinoma, managed in 5 French University Hospitals between 1980 and 2014. We compared surgery and medical management for ACC recurrence.ResultsFifty-nine patients were included, 46 of whom had an initial R0 resection. Twenty-nine patients underwent reoperation for recurrence, while 30 had nonoperative treatments. Operated patients had a greater median overall survival after recurrence than nonoperated patients (91 vs 15 months; P < .001). Patients operated on for local or distant recurrence had similar overall survival (110 vs 91 months; P = .81). In nonoperated patients, types of medical managements did not impact survival. Surgery for recurrence (P = .037) and a disease-free interval between initial resection and recurrence >12 months (P = .059) were both prognostic factors for improved survival, whereas age, stage, and tumor size (P ≥ .2 each) were not. A Ki67 <25% tended to be associated with better overall survival (P = .051).ConclusionBoth surgery for recurrence and disease-free interval between the initial resection of an adrenocortical carcinoma and recurrence >12 months are associated with better overall survival.